<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>LSE:AZN on 无关紧要的宇宙</title><link>https://316140221.github.io/Hugo/zh/tags/lseazn/</link><description>Recent content in LSE:AZN on 无关紧要的宇宙</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Sat, 30 Aug 2025 14:30:00 +0800</lastBuildDate><atom:link href="https://316140221.github.io/Hugo/zh/tags/lseazn/index.xml" rel="self" type="application/rss+xml"/><item><title>Astra Pill Cuts Hard-to-Treat Blood Pressure in Late-Stage Trial</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-08-30-astra-pill-cuts-hard-to-treat-blood-pressure-in-la/</link><pubDate>Sat, 30 Aug 2025 14:30:00 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-08-30-astra-pill-cuts-hard-to-treat-blood-pressure-in-la/</guid><description>AstraZeneca Plc said its experimental hypertension pill reduced blood pressure by more than twice as much as standard treatment in a large late-stage study, bolstering its chances of competing in a cr</description></item><item><title>Astra Pill Cuts Hard-to-Treat Blood Pressure in Late-Stage Trial</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-08-30-astra-pill-cuts-hard-to-treat-blood-pressure-in-la/</link><pubDate>Sat, 30 Aug 2025 14:30:00 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-08-30-astra-pill-cuts-hard-to-treat-blood-pressure-in-la/</guid><description>AstraZeneca Plc said its experimental hypertension pill reduced blood pressure by more than twice as much as standard treatment in a large late-stage study, bolstering its chances of competing in a cr</description></item><item><title>US Expansion Not Driven By Tariffs: AstraZeneca CFO</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-07-29-us-expansion-not-driven-by-tariffs-astrazeneca-cfo/</link><pubDate>Tue, 29 Jul 2025 20:58:43 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-07-29-us-expansion-not-driven-by-tariffs-astrazeneca-cfo/</guid><description>Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the majority of its manufacturing is based in the U.S., which is why it is not being d</description></item><item><title>US Expansion Not Driven By Tariffs: AstraZeneca CFO</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-29-us-expansion-not-driven-by-tariffs-astrazeneca-cfo/</link><pubDate>Tue, 29 Jul 2025 20:58:43 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-29-us-expansion-not-driven-by-tariffs-astrazeneca-cfo/</guid><description>Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the majority of its manufacturing is based in the U.S., which is why it is not being d</description></item><item><title>AstraZeneca's US Investment, Future of Psychedelic Therapy | Bloomberg Businessweek Daily 7/29/2025</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-07-29-astrazenecas-us-investment-future-of-psychedelic-t/</link><pubDate>Tue, 29 Jul 2025 20:41:15 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-07-29-astrazenecas-us-investment-future-of-psychedelic-t/</guid><description>On today&amp;rsquo;s episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca discusses the company&amp;rsquo;s quarterly earnings. Kabir Nath, Chi</description></item><item><title>AstraZeneca's US Investment, Future of Psychedelic Therapy | Bloomberg Businessweek Daily 7/29/2025</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-29-astrazenecas-us-investment-future-of-psychedelic-t/</link><pubDate>Tue, 29 Jul 2025 20:41:15 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-29-astrazenecas-us-investment-future-of-psychedelic-t/</guid><description>On today&amp;rsquo;s episode of Bloomberg Businessweek Daily with Tim Stenovec and Carol Massar, Pascal Soriot, Chief Executive Officer of AstraZeneca discusses the company&amp;rsquo;s quarterly earnings. Kabir Nath, Chi</description></item><item><title>AstraZeneca Profit, Revenue Lifted by Cancer Drugs</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-07-29-astrazeneca-profit-revenue-lifted-by-cancer-drugs/</link><pubDate>Tue, 29 Jul 2025 20:00:14 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-07-29-astrazeneca-profit-revenue-lifted-by-cancer-drugs/</guid><description>AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US. Chief Executive Officer Pascal Soriot has</description></item><item><title>AstraZeneca Profit, Revenue Lifted by Cancer Drugs</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-29-astrazeneca-profit-revenue-lifted-by-cancer-drugs/</link><pubDate>Tue, 29 Jul 2025 20:00:14 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-29-astrazeneca-profit-revenue-lifted-by-cancer-drugs/</guid><description>AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US. Chief Executive Officer Pascal Soriot has</description></item></channel></rss>